Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib + Avelumab in STK11-Mutated NSCLC (LUNG-MAP S1900C)
NCT04173507Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Feb 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talazoparib in non-small cell lung cancer (NSCLC), sponsored by SWOG Cancer Research Network. Primary endpoints: Objective Response Rate and Disease Control Rate at 12 Weeks. Started Feb 2020; status: completed.
02
Drugs
talazoparib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04173507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04173507.